# Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

> **NCT04799353** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 33 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **DRUG:** Budigalimab
- **DRUG:** Placebo
- **DRUG:** Budigalimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04799353
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2022-10-11
- **Final completion:** 2022-10-11
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04799353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04799353, "Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04799353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*